| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
EP2 ≥ 8.5 (pEC50) EP2 ≥ 8.3 (pKi)
PGN-9856 selectively targets the EP2 receptor, a subtype of the prostaglandin E2 (PGE2) receptor. It acts as a potent, non-prostanoid agonist with high affinity (pKi ≥ 8.3). By activating the EP2 receptor, it modulates downstream signaling pathways involved in inflammation and intraocular pressure regulation, which accounts for its anti-inflammatory and anti-glaucomatous activities. |
|---|---|
| ln Vitro |
In vitro, PGN-9856 demonstrates potent agonistic activity at the EP2 receptor, with a pEC50 ≥ 8.5. It shows high selectivity and affinity (pKi ≥ 8.3) for the EP2 receptor over other prostanoid receptors. The compound's activity is characterized in cell-based assays measuring receptor activation and downstream signaling.
|
| ln Vivo |
In vivo, PGN-9856 has shown anti-inflammatory and anti-glaucomatous activities. It is being investigated for its potential to reduce intraocular pressure in glaucoma models and to modulate inflammatory responses. Detailed in vivo efficacy data, including effects on intraocular pressure and inflammation, are described in the primary literature.
|
| Enzyme Assay |
Non-cellular binding assays for PGN-9856 involve measuring its affinity for the EP2 receptor. Binding affinity (pKi ≥ 8.3) is determined using radioligand binding assays with membrane preparations expressing the EP2 receptor. Selectivity profiling against other prostanoid receptors (EP1, EP3, EP4, DP, FP, IP, TP) is also performed to confirm its specificity.
|
| Cell Assay |
In vitro cellular experiments with PGN-9856 are conducted in cell lines expressing the EP2 receptor. Cells are treated with the compound, and receptor activation is assessed by measuring downstream signaling readouts such as cAMP accumulation. The compound's potency (pEC50 ≥ 8.5) is determined from dose-response curves. These assays confirm the compound's efficacy as an EP2 receptor agonist.
|
| Animal Protocol |
In vivo animal studies for PGN-9856 are performed in models of glaucoma and inflammation. For glaucoma research, animal models with elevated intraocular pressure are used to assess the compound's ability to reduce IOP. For inflammation studies, models of acute or chronic inflammation are employed. Endpoints include measurements of intraocular pressure, inflammatory markers, and tissue histology.
|
| ADME/Pharmacokinetics |
PGN-9856 has a molecular formula of C21H15F2NO4 and a molecular weight of 383.34. The CAS number is 863704-91-0. The IUPAC name is 2-(3-(3',4-difluoro-[1,1'-biphenyl]-3-carboxamido)phenoxy)acetic acid. Purity is typically ≥98%. It is soluble in DMSO (125 mg/mL). Storage is at -20°C.
|
| Toxicity/Toxicokinetics |
Standard toxicity assessments for PGN-9856 would be generated during preclinical development. As an EP2 receptor agonist, potential effects on various physiological systems would be monitored. Comprehensive toxicology studies would assess safety margins and identify target organ toxicities. Researchers should consult the safety data sheet and handle the compound with appropriate laboratory safety precautions.
|
| References | |
| Additional Infomation |
intraocular pressure lowering agents
PGN-9856 is a novel, potent, and selective prostaglandin EP2 receptor agonist. A key reference is Coleman RA, et al. "The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors." Br J Pharmacol. 2019. The compound is for research use only and is not for human therapeutic applications. |
| Molecular Formula |
C21H15F2NO4
|
|---|---|
| Molecular Weight |
383.34491276741
|
| Exact Mass |
383.096
|
| CAS # |
863704-91-0
|
| PubChem CID |
59654860
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
547
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C=CC(=CC=1C(NC1C=CC=C(C=1)OCC(=O)O)=O)C1C=CC=C(C=1)F
|
| InChi Key |
HZJWJNHYKNSGAT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H15F2NO4/c22-15-4-1-3-13(9-15)14-7-8-19(23)18(10-14)21(27)24-16-5-2-6-17(11-16)28-12-20(25)26/h1-11H,12H2,(H,24,27)(H,25,26)
|
| Chemical Name |
2-[3-[[2-fluoro-5-(3-fluorophenyl)benzoyl]amino]phenoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~326.08 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6087 mL | 13.0433 mL | 26.0865 mL | |
| 5 mM | 0.5217 mL | 2.6087 mL | 5.2173 mL | |
| 10 mM | 0.2609 mL | 1.3043 mL | 2.6087 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
